Breye Therapeutics
breye.com
Ophthalmology & Eye Clinics
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
26th Euretina Congress
26th Euretina Congress Vienna, Austria 1-4 October 2026 View event website Attending
Read more
Report
Breye Therapeutics Raises €67.5 Million Series A To Advance Danegaptide Into Phase 2
Breye Therapeutics has raised an oversubscribed €67.5 million Series A financing to advance its lead retinal disease candidate danegaptide into a randomized Phase 2 clinical trial. The round was co-led by new investor Mission BioCapital and existing inves
Read more
Report
Denmark's Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Read more
Report
Pill May Prevent Sight Loss in Diabetic Eye Condition
Researchers at Trinity College Dublin, in collaboration with Breye Therapeutics, have found that an oral medication ("Danegaptide") can protect
Read more
Report
Report
Report
Report
Breye raises €67.5M for diabetic eye disease trial with Novo Holdings backing
Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial.
Read more
Report
Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
Co-led by new investor Mission BioCapital and existing investor Novo Holdings,with additional investment from existing syndicate member Sound Biov...
Read more
Report
Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
Co-led by new investor Mission BioCapital and existing investor Novo Holdings,with additional investment from existing syndicate member Sound Bioventures, and new investors the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Mod
Read more
Report
Show more news
Financials
Total raised
$72.9M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | $72.9M | Details |